PCVX.US Vaxcyte Inc

Healthcare Biotechnology USA Stocks
63.37 USD
Close of Nov 15, 2026
42.40 90.75
Market cap
USD 10.0B
P/E
-
P/B
4.03x
ROE
-48.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PCVX.US undervalued?

Graham number

The Graham number of Vaxcyte Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vaxcyte Inc fundamental analysis

No fundamental analysis for Vaxcyte Inc yet.

Vaxcyte Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; …

Full company profile